TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34256732

Group type: EXPERIMENTAL
Intervention: Lung cancer patients receiving immunotherapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lung cancer patients not suffering from irAEs
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Responders to combined chemoimmunotherapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Responders to chemoimmunotherapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Longitudinal samples from lung cancer patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 34
Study: 34256735

Group type: EXPERIMENTAL
Intervention: Hospitalized participants
Number of subjects: 119

Group type: COMPARATOR
Intervention: Non-hospitalized participants
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: All participants at 90-174 days post SARS-CoV-2 diagnosis
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Hospitalized participants at 90-174 days post SARS-CoV-2 diagnosis
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Participants assessed with symptom surveillance questionnaire
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Participants with persistent symptoms
Number of subjects: 119
Study: 34256822

Group type: EXPERIMENTAL
Intervention: Central venous oxygen saturation monitoring
Number of subjects: 0
Study: 34256967

Group type: EXPERIMENTAL
Intervention: Guideline recommendations for first- to nth-line treatment of target mental health symptoms.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidance on addressing environmental factors and possible underlying diagnoses.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Approach to prescribing guidelines that incorporates real-world availability of treatments.
Number of subjects: 0
Study: 34257421

Group type: EXPERIMENTAL
Intervention: N-acetylmannosamine (ManNAc)
Number of subjects: 12
Study: 34258059

Group type: EXPERIMENTAL
Intervention: APACHE IV
Number of subjects: 103

Group type: COMPARATOR
Intervention: APACHE II
Number of subjects: 103
Study: 34258383

Group type: EXPERIMENTAL
Intervention: Total plaque burden quantified by CCTA
Number of subjects: 125
Study: 34258411

Group type: EXPERIMENTAL
Intervention: Transperineal ultrasound (TPUS)
Number of subjects: 22
Study: 34258507

Group type: EXPERIMENTAL
Intervention: Romosozumab after 12 months of denosumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 0
Study: 34259012

Group type: EXPERIMENTAL
Intervention: Corrected ASD patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 34259020

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study: 34259039

Group type: EXPERIMENTAL
Intervention: Supplemental Automated Whole-Breast Ultrasound
Number of subjects: 0
Study: 34259164

Group type: EXPERIMENTAL
Intervention: Web-based psychotherapy plus treatment as usual (8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual exclusively
Number of subjects: 60
Study: 34259448

Group type: EXPERIMENTAL
Intervention: Stratification for identification of Prognostic categories In the acute RESpiratory distress syndrome score
Number of subjects: 1301
Study: 34259588

Group type: EXPERIMENTAL
Intervention: Floodlight Proof-of-Concept (PoC) app
Number of subjects: 76
Study: 34259655

Group type: EXPERIMENTAL
Intervention: Prone-positioning during ECMO
Number of subjects: 298

Group type: COMPARATOR
Intervention: No prone-positioning during ECMO
Number of subjects: 298
Study: 34259664

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (gas flow 0; 30-60 L/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (decreasing respiratory rate)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (mouth closed)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (various conditions)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Time-of-flight camera (RRTOF)
Number of subjects: 10
Study: 34259921

Group type: EXPERIMENTAL
Intervention: Machine learning risk score model for mortality prediction
Number of subjects: 3683

Group type: EXPERIMENTAL
Intervention: Machine learning risk score model
Number of subjects: 3683
Study: 34259915

Group type: EXPERIMENTAL
Intervention: Ankylosing spondylitis patients (Group 1)
Number of subjects: 60
Study: 34260044

Group type: EXPERIMENTAL
Intervention: Psoriasis Symptoms and Impacts Measure (P-SIM)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: P-SIM
Number of subjects: 1002
Study: 34260061

Group type: EXPERIMENTAL
Intervention: Right supraclavicular fossa ultrasound view used for guidewire positioning
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Guidewire J-tip positioning
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance for correcting misplaced guidewires
Number of subjects: 103
Study: 34260435

Group type: EXPERIMENTAL
Intervention: Bilateral Hearing Aids (BiHA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Bilateral Cochlear Implants (BiCI)
Number of subjects: 56
Study: 34260480

Group type: EXPERIMENTAL
Intervention: Respiratory Syncytial Virus (RSV) positive test
Number of subjects: 225

Group type: COMPARATOR
Intervention: Influenza
Number of subjects: 225

Group type: COMPARATOR
Intervention: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Number of subjects: 225
Study: 34260706

Group type: EXPERIMENTAL
Intervention: CSF tTau
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CSF pTau
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CSF NfL
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CSF Ab42/40-ratio
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CSF NfL (sensitivity analysis excluding spinal cord ischemia)
Number of subjects: 32
Study: 34260823

Group type: EXPERIMENTAL
Intervention: 8-week pulmonary telerehabilitation programme including online training for 2 weeks and offline self-managed rehabilitation for 6 weeks.
Number of subjects: 0
Study: 34260835

Group type: EXPERIMENTAL
Intervention: Deep-learning models and a natural-language model applied to decode speech from cortical activity.
Number of subjects: 1
Study: 34260994

Group type: EXPERIMENTAL
Intervention: Fear conditioning and extinction task during fMRI
Number of subjects: 76
Study: 34261044

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 7
Study: 34261348

Group type: EXPERIMENTAL
Intervention: CamAPS FX closed-loop system
Number of subjects: 18
Study: 34261508

Group type: EXPERIMENTAL
Intervention: E-MOTIVE bundle (1) Early PPH detection using a calibrated drape, (2) uterine Massage, (3) Oxytocic drugs, (4) Tranexamic acid, (5) Intra Venous fluids, (6) genital tract Examination and escalation when necessary.
Number of subjects: 0
Study: 34261638

Group type: EXPERIMENTAL
Intervention: Ultra-processed food intake (≥5 servings/day)
Number of subjects: 116087

Group type: EXPERIMENTAL
Intervention: Ultra-processed food intake (1-4 servings/day)
Number of subjects: 116087

Group type: EXPERIMENTAL
Intervention: Soft drinks, refined sweetened foods, salty snacks, processed meat (subgroups of ultra-processed food)
Number of subjects: 116087

Group type: COMPARATOR
Intervention: Intakes of white meat, red meat, dairy, starch, fruit, vegetables, and legumes
Number of subjects: 116087
Study: 34261680

Group type: EXPERIMENTAL
Intervention: Qualitative methods (observation, semistructured interviews, focus groups) and quantitative method (retrospective cohort)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative data analysis using thematic analysis derived from a grounded theory approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative data analysis using descriptive statistics
Number of subjects: 0
Study: 34261684

Group type: EXPERIMENTAL
Intervention: Electronic Frailty Index (eFI) derived from electronic health records (EHR) data
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Test-based clinical Frailty Instrument
Number of subjects: 1000
Study: 34261689

Group type: EXPERIMENTAL
Intervention: Nutritional support and rehabilitation for COVID-19 survivors
Number of subjects: 549
Study: 34261767

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (NSPT)
Number of subjects: 20
Study: 34261794

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (HSCT) without myeloablation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Postmortem examination of a child with γc-SCID after HSCT
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Observation of tertiary lymphoid organs
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Detection of RAR-related orphan receptor-positive LTi cells
Number of subjects: 9
Study: 34261955

Group type: EXPERIMENTAL
Intervention: mPESS at least 5 (high probability of severe periodontitis)
Number of subjects: 32285

Group type: EXPERIMENTAL
Intervention: Nonreplaced missing teeth
Number of subjects: 32285

Group type: EXPERIMENTAL
Intervention: Regular annual visit to the dentist
Number of subjects: 32285
Study: 34261986

Group type: EXPERIMENTAL
Intervention: Single-piece monofocal hydrophobic acrylic intraocular lens (IOL) with hydroxyethyl methacrylate (HEMA)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Automated preloaded delivery system
Number of subjects: 384
Study: 34262299

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25mcg (Group 1)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 200/62.5/25mcg (Group 2)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Step-up group (from Group 1 to 200/62.5/25mcg)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (both groups)
Number of subjects: 111
Study: 34262403

Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 mg twice daily orally for 21 days (day 5-25 of each menstrual cycle) for 4 cycles
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Number of subjects: 52
Study: 34262514

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)-based preventive group intervention: EMOTION
Number of subjects: 0
Study: 34262694

Group type: EXPERIMENTAL
Intervention: Transepidermal water loss (TEWL)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Stratum corneum hydration (SCH)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Skin pH
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Sebum content
Number of subjects: 418
Study: 34262758

Group type: EXPERIMENTAL
Intervention: Supervised 24-week cardiovascular and resistance exercise intervention
Number of subjects: 22
Study: 34263020

Group type: EXPERIMENTAL
Intervention: PR-T 0.2 mg/kg/d (Arm 1)
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: PR-T 0.15-0.175 mg/kg/d plus basiliximab (Arm 2)
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: PR-T 0.2 mg/kg/d delayed until day 5 posttransplant plus basiliximab (Arm 3)
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate
Number of subjects: 856
Study: 34263213

Group type: EXPERIMENTAL
Intervention: Music therapy (n=30), applied three times a week for the first 2 weeks
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercise (n=28), applied three times a week for the first 2 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (n=28), no intervention
Number of subjects: 86
Study: 34263236

Group type: EXPERIMENTAL
Intervention: TEMpEST-Transitional Care Model Stroke Turkey interventions including at least 3 face-to-face interviews at the hospital, distance education via web, and telephone communications for 3 months, and 1 home visit within 7 days of discharge
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 70
Study: 34263302

Group type: EXPERIMENTAL
Intervention: Modified MIRPE technique for surgical correction of pectus excavatum (PE)
Number of subjects: 47
Study: 34263665

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (previous treatments)
Number of subjects: 0
Study: 34263701

Group type: EXPERIMENTAL
Intervention: Embolic protection devices (EPDs) during TAVR procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: No embolic protection devices (EPDs) during TAVR procedures
Number of subjects: 0
Study: 34263738

Group type: EXPERIMENTAL
Intervention: Thrombomodulin
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: IL-2, IL-10, IL-22, CXCL10, Fas-ligand, MMP9
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Granulocyte CSF (G-CSF), S100A8, IL-6
Number of subjects: 311
Study: 34264412

Group type: EXPERIMENTAL
Intervention: LY3076226 at doses ranging from 0.2-5.0 mg/kg as an intravenous infusion on Day 1 of each 21-day cycle.
Number of subjects: 25
Study: 34264732

Group type: EXPERIMENTAL
Intervention: Integrated cannabis and anxiety reduction treatment (ICART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MET-CBT alone
Number of subjects: 0
Study: 34264743

Group type: EXPERIMENTAL
Intervention: Highest quartile of plasma BCAAs
Number of subjects: 19472

Group type: COMPARATOR
Intervention: Lowest quartile of plasma BCAAs
Number of subjects: 19472
Study: 34264864

Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI) with 3.2 × 10^3 Plasmodium falciparum sporozoites
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI)
Number of subjects: 161
Study: 34264865

Group type: EXPERIMENTAL
Intervention: 60 mg oral methylphenidate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Higher D1R availability in caudate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Higher D2/3R availability in nucleus accumbens (NAc)
Number of subjects: 32
Study: 34264973

Group type: EXPERIMENTAL
Intervention: Storytelling intervention group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Community health workers
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Health care workers
Number of subjects: 96
Study: 34265048

Group type: EXPERIMENTAL
Intervention: 9-valent HPV (9vHPV) vaccine types
Number of subjects: 1399
Study: 34265151

Group type: EXPERIMENTAL
Intervention: Prophylactic 3D funnel-shaped intraperitoneal mesh
Number of subjects: 76

Group type: COMPARATOR
Intervention: No prophylactic mesh (Control)
Number of subjects: 76
Study: 34265220

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34265285

Group type: EXPERIMENTAL
Intervention: Methylation index of HOXA1 (MI_H)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Methylation index of NEUROG1 (MI_N)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Brush cytology
Number of subjects: 67

Group type: COMPARATOR
Intervention: Serum carbohydrate antigen 19-9 (CA19-9)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combination of brush cytology, MI_H, MI_N, and CA19-9
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Methylation markers
Number of subjects: 67
Study: 34265394

Group type: EXPERIMENTAL
Intervention: High-field MR-Linac treatment
Number of subjects: 943
Study: 34265433

Group type: EXPERIMENTAL
Intervention: Ensartinib at a dose of 225 mg once daily
Number of subjects: 59
Study: 34266311

Group type: EXPERIMENTAL
Intervention: Surgical or transcatheter aortic valve replacement
Number of subjects: 0
Study: 34266343

Group type: EXPERIMENTAL
Intervention: Brain fitness (B-Fit) utilizing education and goal setting
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Education-only
Number of subjects: 130

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 130
Study: 34266389

Group type: EXPERIMENTAL
Intervention: Community-based football program
Number of subjects: 39
Study: 34266407

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Number of subjects: 49

Group type: COMPARATOR
Intervention: Gemox
Number of subjects: 49
Study: 34266444

Group type: EXPERIMENTAL
Intervention: Uncemented Attune mobile bearing TKA
Number of subjects: 0
Study: 34266463

Group type: EXPERIMENTAL
Intervention: Upright Walking Task
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Forward Leaning Trunk (FLT) Walking Task
Number of subjects: 55

Group type: COMPARATOR
Intervention: nLBP group
Number of subjects: 55
Study: 34266505

Group type: EXPERIMENTAL
Intervention: VigilanS brief contact intervention (BCI) including resource cards, telephone calls, and postcards
Number of subjects: 10666

Group type: EXPERIMENTAL
Intervention: VigilanS brief contact intervention (BCI)
Number of subjects: 10666
Study: 34266583

Group type: EXPERIMENTAL
Intervention: Orodispersible Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34266694

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 350
Study: 34266842

Group type: EXPERIMENTAL
Intervention: Data collection from participants during the first 72 hours of hospitalization, including vital parameters and electrophysiological waveforms.
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Follow-up data collection at 3 months, 1 year, 2 years, and 5 years after ED visit.
Number of subjects: 151
Study: 34266941

Group type: EXPERIMENTAL
Intervention: CVR max (highest CPM volume ratio) in term infants (n=351)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: CVR max and gestational age in preterm infants (n=32)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: CVR first (first CPM volume ratio)
Number of subjects: 383
Study: 34266942

Group type: EXPERIMENTAL
Intervention: Awake prone positioning (n=505)
Number of subjects: 827

Group type: COMPARATOR
Intervention: Awake supine positioning (n=322)
Number of subjects: 827
Study: 34266943

Group type: EXPERIMENTAL
Intervention: AI-driven volumetric quantification of CF-related modifications
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Novel scoring system for disease outcome
Number of subjects: 184
Study: 34267079

Group type: EXPERIMENTAL
Intervention: Next generation epigenetic modulators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synergistic drug combination regimens
Number of subjects: 0
Study: 34268122

Group type: EXPERIMENTAL
Intervention: Systemic Immune-Inflammation Index (SII) > 510
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Nomogram based on SII and other factors (CA19-9, tumor differentiation, T stage, N stage, margin status)
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 1072
Study: 34268321

Group type: EXPERIMENTAL
Intervention: Self-testing for HIV
Number of subjects: 0
Study: 34268359

Group type: EXPERIMENTAL
Intervention: Amnion group (Foley catheter with sterilized freeze-dried amnion graft)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Foley catheter without amnion graft)
Number of subjects: 30
Study: 34268393

Group type: EXPERIMENTAL
Intervention: Lung injury burden (LIB) in survivors
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: SNP/InDels
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: LIB combined with APACHE II score
Number of subjects: 105
Study: 34268406

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 88

Group type: COMPARATOR
Intervention: High-dose octreotide
Number of subjects: 88
Study: 34268426

Group type: EXPERIMENTAL
Intervention: Adjunctive treatments including types of oxygen support, ventilation, rescue therapies for hypoxemia, other adjunctive and supportive treatments, experimental therapies
Number of subjects: 0
Study: 34268513

Group type: EXPERIMENTAL
Intervention: Therapeutic heparin
Number of subjects: 465

Group type: COMPARATOR
Intervention: Prophylactic heparin
Number of subjects: 465
Study: 34268623

Group type: COMPARATOR
Intervention: Dexmedetomidine 0.5 ng/mL
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dexmedetomidine 1.0 ng/mL
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dexmedetomidine 1.5 ng/mL
Number of subjects: 11
Study: 34268711

Group type: EXPERIMENTAL
Intervention: IMC-001 (PD-L1 blocker) administered intravenously every 2 weeks at doses ranging from 2 to 20 mg/kg
Number of subjects: 15
Study: 34269152

Group type: EXPERIMENTAL
Intervention: Acalabrutinib and Vistusertib combination therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Acalabrutinib
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vistusertib
Number of subjects: 25

Group type: COMPARATOR
Intervention: Circulating tumor DNA dynamics
Number of subjects: 25
Study: 34269698

Group type: EXPERIMENTAL
Intervention: Liquid chromatography-tandem mass spectrometry method for monitoring medication adherence
Number of subjects: 92
Study: 34269712

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate ketogenic diet (LCKD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34269847

Group type: EXPERIMENTAL
Intervention: Radiotherapy to the prostate region
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Radiotherapy to prostate and pelvic nodal regions
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Larger irradiated volumes
Number of subjects: 18
Study: 34269908

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 34269911

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) added to catheter ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Catheter ablation alone
Number of subjects: 0
Study: 34269927

Group type: EXPERIMENTAL
Intervention: Intravenous tocilizumab (IV-TCZ) 4 mg/kg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Baseline US34-PDUS
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: US34-PDUS, CDAI, DAS28-ESR
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Baseline PDUS and 12-week PDUS change
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DAS28-ESR and CDAI
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HAQ-DI
Number of subjects: 54
Study: 34270325

Group type: EXPERIMENTAL
Intervention: High sugar-sweetened beverage (SSB) consumers
Number of subjects: 122819

Group type: COMPARATOR
Intervention: Control group (lower SSB consumers)
Number of subjects: 122819
Study: 34270347

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitors and Insulin Pumps
Number of subjects: 0
Study: 34270444

Group type: EXPERIMENTAL
Intervention: Internet-delivered digital trainings prior to and during rehabilitation stay
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Psychosomatic rehabilitation treatment
Number of subjects: 1812

Group type: COMPARATOR
Intervention: General population
Number of subjects: 1812